pharma · Prurigo Nodularis · Uremic Pruritus · TRVI
Trevi Therapeutics
Trevi Therapeutics patent portfolio — 7 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 195 Church Street, 16th Floor, New Haven, CT 06510, US
- Founded
- 2011
- Employees
- 45
- Programs
- 11
- Drugs
- 8
- Patents
- 7
Trevi Therapeutics patents
7 pharmaceutical patents indexed for Trevi Therapeutics. 0 expire within 24 months.
Trevi Therapeutics has 7 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12274696
Methods of administering nalbuphine
granted -
US 11660296
Treatment of chronic cough, breathlessness and dyspnea
granted -
US 10238646
Methods for treating pruritus
granted -
US 9624233
Compounds for treating pruritic conditions
granted -
US 8987289
Methods for treating pruritus
granted -
US 8940753
Methods for treating pruritis
granted -
US 8637538
Methods for treatment of pruritis
granted
Frequently asked questions
How many patents does Trevi Therapeutics have?
7 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Trevi Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.